Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
This was the stock's third consecutive day of losses.
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors
This was the stock's second consecutive day of losses.
Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...
Bristol Myers Squibb Tops Q4 Estimates
Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.
Bristol-Myers Squibb (NYSE:BMY) Posts Better-Than-Expected Sales In Q4 But Full-Year Sales Guidance Misses Expectations
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q4 CY2024, with sales up ...
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...
What's Going On With Bristol Myers Squibb Stock On Monday?
Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...
Bristol-Myers Squibb's SWOT analysis: stock outlook mixed amid pipeline progress
Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds ...
Bristol Myers Squibb (BMY) Q4 2024 Earnings Call Transcript
Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this ...
Bristol-Myers Squibb Stock Falls After Weak Guidance
Shares in Bristol-Myers Squibb traded about 2.7% lower Thursday after the drug maker gave 2025 guidance that undershot ...
Fierce Pharma1d
Bristol Myers Squibb comes up short in bid to expand Opdualag in melanoma
Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...